Metabolism of the tricyclic antidepressant amitriptyline by cdna-expressed human cytochrome p450 enzymes

Pharmacology

Volumn 55, Issue 5, 1997, Pages 235-243

  Olesen, Ole V ^a   Linnet, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Amitriptyline; Cytochrome P450; Metabolism, amitriptyline

Indexed keywords

AMITRIPTYLINE; COMPLEMENTARY DNA; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; DRUG METABOLIZING ENZYME; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; LIVER; PRIORITY JOURNAL;

EID: 0030735733     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139533     Document Type: Article

References (25)

1. Bertilsson L, Dahl M-L: Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CNS Drugs 1996:5:200-223.
2. Skjelbo E. Brosen K. Hallas J. Grant LF: The mephenytoin oxidation polymorphism is partially responsible for the N-demcthylation of imipramine. Clin Pharmacol Ther 1991: 49:18-23.
3. Koyama E, Tanaka T. Chiba K. Ka-wakatsu S. Morinobu S, Totsuka S. Ishizaki T: Steady-state plasma concentrations of imipramine and desi-prantine in relation to S-mephcny-toin 4'-hydroxvlation status in Japanese depressive patients. J Clin Psy-chopharmacol 1996:16:286-293.
4. Chiba K, Saitoh A, Koyama E, Tani M. Hayashi M. Ishizaki T: The role of S-mephenvtoin 4'-hydroxvlase in imipramine metabolism by human liver microsomes: A two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. BrJ Clin Pharmacol 1994:37:237-242.
5. Brosen K. Zeugin T. Meyer UA: Role of P45011D6. the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991:49:609-617.
6. Lemoine A. Gautier JC, Azoulay D, Kiffel L, Belloc C. Gucngerich FP. Maurel P, Beaune P. Leroux JP: Major pathway of imipramine metabolism is catalyzed by cytochromes P450 IA2 and P450 3A4 in human liver. Mol Pharmacol 1993:43:827-832.
7. Coutts RT, Su P. Baker GB: Involvement of CYP2D6. CYP3A4. and other cytochrome P450 enzymes in N-dcalkylation reaction. J Pharmacol Toxicol Methods 1994; 31:177-186.
8. Breyer-Pfaf TU, Pfandl B. Nill K. Nussecr E, Monney C. Jonzier-Per-ey M. Baettig D. Baumann P: Enan-tioselectivc amitriptyline metabolism in patients phenotvped for two cytochrome P450 isozymes. Clin Pharmacol Thcr 1992:52:350-358.
9. Ghahramani P, Ellis SW. Lennard MS. Ramsay LE, Tucker GT: Cytochromes P450 mediating the N-de-methylation of amitriptyline. Br J Clin Pharmacol 1997:43:137-144.
10. Schmider J. Greenblatt DJ. von Moltke LL. Harmatz JS, Shader Rl: N-Demethylation of amitriptyline in vitro: Role of cytochrome P450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol ExpTher 1995:275:592-597.
11. Riem HH. Chen J. Freiburghaus AU. Follath F: Metabolism of theophylline by cDNA-expressed human cytochromes P450. Br J Clin Pharmacol 1995:39:321-326.
12. Fuhr U, Doehmer J. Battula N, Wolfcr C. Kudla C, Keila Y. Staib AH: Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 1992: 43:225-235.
13. Leemann T. Transon C. Dayer P; Cytochrome P450TB (CYP2C): A major monooxvgenase catalyzing diclofenac 4'-hydroxylalion in human liver. LifeSci 1993;52:29-34.
14. Hall SD. Guengerich FP. Branch RA. Wilkinson GR: Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. .J Pharmacol Exp Thcr 1987;240:216-222.
15. Kim RB, O’Shea D. Wilkinson GR: Intcrindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic hydroxylation in men and women and its rclat onship to CYP2EI genetic polymorphisms. Clin Pharmacol Ther 1995:57:645-655.
16. Dahl M-L. Nordin C. Bertilsson L: Enantiosclcctivc hydroxylation of nortriptyline in human liver microsomes. intestinal homogenate, and patients treated with nortriptyline. Thcr Drug Mon it 1991:13:189-194.
17. Schmider J, Greenblatt DJ. von Moltke LL, Shader RI: Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in humans. J Clin Psychopharmacot 1996; 16: 267-272.
18. Shimada T. Yamazaki Y. Mimura M. Inui Y. Guengerich FP: Interindividual variations in human liver cytochrome P 450 isozymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes in 30 Japanese and 30 Caucasians. J Pharmacol ExpTher 1994:270:414-423.
19. Goldstein JA. Faletto MB. Romkes-Sparks M. Sullivan TL. Kitareewan S. Raucy JL, Lasker JM, Ghanayem Bl: Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxy-lasc in humans. Biochemistry 1994: 33:1743-1752.
20. Task Force on the Use of Laboratory Tests in Psychiatry: Tricyclic antidepressant blood level measurements and clinical outcome: An APA Task Force Report. Am.1 Psychiatry 1985;142:155-162.
21. Pounder DJ. Adams E. Fuke C. Langford AM: Site to site variability of postmortem drug concentrations in liver and lung. J Forensic Sei 1996:41:927-932.
22. Basell RC. Cravey RH (eds): Amitriptyline: in: Disposition of Toxic Drugs and Chemicals in Man. Foster City. Chemical Toxicology Institute. 1995, pp 35-39.
23. Mcllslröm B, Wäwe J. Bertilsson L, Sjöqvist F: Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986;39:369-371.
24. Schmider J, Greenblatt DJ, Harmatz JS. Shader Rl: Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to ami-triptylin N-dcmethylation. Br J Clin Pharmacol 1996;41:593-604.
25. Skjelbo E. Brosen K: Inhibition of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-261.